£4 million funding for Diagnostic Evidence Co-operatives 

The National Institute for Health Research has announced £4 million of funding over 4 years from 1st September 2013 for 4 new Diagnostic Evidence Co-operatives to improve the way diseases are diagnosed. This will help patients access the most appropriate treatments more quickly and help the NHS make the best use of its resources.

The Diagnostic Evidence Co-operatives will bring together a wide range of experts and specialists from across the NHS and industry, including clinicians and other healthcare professionals, patients, NHS commissioners and researchers and investigate a number of different clinical areas. These clinical areas will be where evidence of the clinical validity, clinical utility, cost-effectiveness and care pathway benefits of in vitro diagnostic medical devices (IVDs) has the potential to lead to improvements in healthcare services and the quality of life of NHS patients. Led by a Clinical Director, and involving multidisciplinary teams, they will facilitate collaborative working with clinicians and other healthcare professionals, the IVD industry, staff of at least one accredited provider of NHS pathology services, NHS commissioners, academic researchers including health economists, and patient-groups.

This initiative supports the Government’s Strategy for UK Life Sciences, which aims to provide a better environment for life sciences, improve the lives of patients and contribute to the UK’s economic growth, enabling patients to access novel treatments earlier.

The four Diagnostic Evidence Co-operatives will be:

  • Imperial College Healthcare NHS Trust which will be looking at Cancer, Cardiovascular diseases, Gut health, Infectious diseases, Metabolic medicine, Primary Care and Respiratory diseases.
  • Oxford Health NHS Foundation Trust which will be looking at Primary care IVDs:  Horizon scanning and rapid reviews to identify new and emerging IVDs, Identifying unmet needs for IVDs, Integrating primary care with laboratory services, Patient, carer and clinician factors in implementing IVDs, improving evidence for primary care IVDs.  
  • Leeds Teaching Hospitals NHS Trust which will be looking at Liver Diseases, Musculoskeletal Diseases and Renal Diseases.
  • Newcastle upon Tyne Hospitals NHS Foundation Trust which will be looking at Cancer, Cardiovascular disease and stroke, Genetics, Infection, Liver Disease, Musculoskeletal Disease, Respiratory Disease and Transplantation.


Sign up to our e-newsletter for all the latest news and updates from Medipex.

*All fields are required